The commitment to safeguard the prescribed treatment protocols of doctors in government clinics and hospitals, particularly for individuals with chronic illnesses, the Ministry of Health have affirmed the ongoing provision of medicines, medical supplies and equipment to ensure optimal healthcare services for both patients and visitors.
The sources told Al-Qabas daily, that the Ministry, in its dedicated role of supplying medicines and medical materials, has recently secured the necessary approvals from regulatory bodies for the procurement of distinct medications designed for the treatment of cancer and heart ailments. The total value of these approvals exceeds 12 million dinars.
They further disclosed that the authorization encompassed the import of multiple drugs catering to cancer patients, each offered at varying price points. The Ministry of Health places significant emphasis on patient safety and seeks to ensure a seamless continuation of treatment for all patients across healthcare facilities.
In addition to the above, recent endorsements encompassed the supply of medications for diabetes patients within centers and hospitals, totaling 3.8 million dinars. Additionally, medicines intended for addressing respiratory conditions were approved, amounting to 3.6 million dinars.
Treatments targeting heart conditions and high blood pressure were allocated a budget of 5.2 million dinars. Medications designed for rheumatoid patients also got the green light, with a budget of 2 million dinars. Moreover, imminent plans include the provision of medicines for patients suffering from anemia within healthcare facilities, at a cost of 2.2 million dinars.
The sources emphasized the stringent guidelines issued to authorities within centers and hospitals, directing them to closely monitor the distribution of medication and medical supplies through their respective pharmacies. This meticulous oversight aims to prevent any misuse or wastage in order to safeguard public funds.
Meanwhile, the Ministry maintains a vigilant stance on addressing any feedback related to the scarcity or absence of specific pharmaceutical items across its facilities.